Guerbet is a global leader in medical imaging, offering a comprehensive range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. For nearly a century, Guerbet has been committed to innovation and improving patient outcomes by providing healthcare professionals with advanced tools for diagnosing and treating a wide range of conditions. Their portfolio includes contrast agents for X-ray, MRI, and ultrasound, along with injectors, catheters, guidewires, and digital solutions designed to enhance imaging procedures and clinical decision-making.
Serves as the central hub for Guerbet's global strategy, corporate governance, research and development leadership, and overall management of its worldwide operations in diagnostic and interventional imaging.
A modern facility designed to foster innovation and collaboration, likely equipped with advanced research laboratories and administrative offices supporting its global functions. Specific architectural details are proprietary.
The work culture at Guerbet's headquarters is likely characterized by a strong emphasis on scientific excellence, innovation in medical technology, a commitment to patient well-being, and a collaborative, international environment driven by its global presence.
The Villepinte headquarters is significant as it represents the nerve center of Guerbet's nearly century-long dedication to advancing medical imaging, coordinating its efforts to improve diagnostic accuracy and treatment outcomes worldwide.
Guerbet operates globally, with a strong presence in Europe, North America, Latin America, Asia-Pacific, and the Middle East/Africa. This worldwide network supports sales and marketing, research and development collaborations, manufacturing (in France, USA, Brazil, Ireland), and distribution of its comprehensive portfolio of contrast media, medical devices (injectors, catheters, guidewires), and digital solutions for diagnostic and interventional imaging.
BP 57400, 15 rue des Vanesses
Villepinte
Île-de-France (Seine-Saint-Denis department)
France
Address: Guerbet LLC, 111 Carnegie Center, Suite 200, Princeton, NJ 08540, USA
Key hub for managing commercial activities and customer relations within the significant US healthcare sector.
Address: Guerbet Japan K.K., Kurosaki Bldg 7F, 4-1-4 Akasaka, Minato-ku, Tokyo 107-0052, Japan
Strategic office for serving the advanced Japanese medical imaging market and expanding Guerbet's presence in the Asia-Pacific region.
Address: Guerbet GmbH, Otto-Volger-Str. 11, 65843 Sulzbach (Taunus), Germany
Critical for engaging with German healthcare providers and strengthening Guerbet's market share in Central Europe.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Guerbet' leadership includes:
Guerbet has been backed by several prominent investors over the years, including:
Guerbet has made several key executive appointments in the past year (May 2023 - May 2024), strengthening its leadership in Finance, Interventional Imaging, Human Resources, and Digital & IT. There was also a notable departure in operations leadership.
Discover the tools Guerbet uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Guerbet commonly utilizes the email format '[first].[last]@guerbet.com' for its employees. While other formats might exist in specific contexts, this is the most frequently observed structure for professional communication.
[first].[last]@guerbet.com
Format
firstname.lastname@guerbet.com
Example
85%
Success rate
Guerbet Press Release • April 24, 2024
Guerbet announced its first-quarter 2024 revenue of €188.5 million, up 6.7% at constant exchange rates and 6.0% on a reported basis. This growth was primarily driven by strong sales of Elucirem™ (Gadopiclenol) in the United States and continued robust performance of Optiray®....more
Guerbet Press Release • December 12, 2023
Guerbet and Bracco Imaging entered into a collaboration agreement for the manufacturing and commercialization of Gadopiclenol in the United States. Guerbet will commercialize Elucirem™ and Bracco will commercialize VUEWAY™, both innovative macrocyclic gadolinium-based contrast agents containing Gadopiclenol....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Guerbet, are just a search away.